1,239
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Cardioprotective activity of standardized extract of Ficus racemosa stem bark against doxorubicin-induced toxicity

&
Pages 468-473 | Received 28 Mar 2011, Accepted 09 Aug 2011, Published online: 02 Dec 2011

Figures & data

Figure 1.  HPLC chromatogram of sequential acetone extract. The HPLC chromatogram was separated on a RP-C18 column (250 × 4.6 mm2; 5 µm) using gradient elution-water and acetonitrile at a total flow rate of 1.0 mL min−1; gradient composition (min,% acetonitrile): 0, 20%; 5, 40%; 8, 75%; 12, 90%;15, 95%; 25, 95%; 27, 20%; 30, 20%. The chromatogram at 270 nm was analyzed and compared.

Figure 1.  HPLC chromatogram of sequential acetone extract. The HPLC chromatogram was separated on a RP-C18 column (250 × 4.6 mm2; 5 µm) using gradient elution-water and acetonitrile at a total flow rate of 1.0 mL min−1; gradient composition (min,% acetonitrile): 0, 20%; 5, 40%; 8, 75%; 12, 90%;15, 95%; 25, 95%; 27, 20%; 30, 20%. The chromatogram at 270 nm was analyzed and compared.

Table 1.  Effect of FRSACE on key cardiac and hepatic enzymes in serum.

Figure 2.  The TBARS levels in serum and heart. Data expressed as mean ± SD of n = 6 rats (p ≤ 0.05); FR250: FRSACE 250 mg kg−1, FR500: FRSACE 500 mg kg−1, AR100: Arjuna 100 mg kg−1, Dox: doxorubicin. Bars carrying different letters a, b, c differ significantly from each other (p ≤ 0.05).

Figure 2.  The TBARS levels in serum and heart. Data expressed as mean ± SD of n = 6 rats (p ≤ 0.05); FR250: FRSACE 250 mg kg−1, FR500: FRSACE 500 mg kg−1, AR100: Arjuna 100 mg kg−1, Dox: doxorubicin. Bars carrying different letters a, b, c differ significantly from each other (p ≤ 0.05).

Figure 3.  Glutathione levels in serum and heart. Data expressed as mean ± SD of n = 6 rats (p ≤ 0.05); FR250: FRSACE 250 mg kg−1, FR500: FRSACE 500 mg kg−1, AR100: Arjuna 100 mg kg−1, Dox: doxorubicin. Bars carrying different letters a, b, c differ significantly from each other (p ≤ 0.05).

Figure 3.  Glutathione levels in serum and heart. Data expressed as mean ± SD of n = 6 rats (p ≤ 0.05); FR250: FRSACE 250 mg kg−1, FR500: FRSACE 500 mg kg−1, AR100: Arjuna 100 mg kg−1, Dox: doxorubicin. Bars carrying different letters a, b, c differ significantly from each other (p ≤ 0.05).

Figure 4.  (A) Section of the heart of Dox-treated rats showing inflammatory changes. (B) Section of the heart of control rats showing normal cardiac muscle fibers with vesicular nuclei. (C) Section of the heart of FRSACE (250 mg kg−1) + Dox-treated rats showing congested blood vessels and inflammatory changes. (D) Section of the heart of Arjuna (100 mg kg−1) + Dox-treated rats showing inflammatory changes. (E) Section of the heart of FRSACE (500 mg kg−1) + Dox-treated rats showing normal cardiac muscle fibers and some congested blood vessels; NMF: normal cardiac muscle fibers, PNMI: perivascular mononuclear infiltrate, CBV: congested blood vessel.

Figure 4.  (A) Section of the heart of Dox-treated rats showing inflammatory changes. (B) Section of the heart of control rats showing normal cardiac muscle fibers with vesicular nuclei. (C) Section of the heart of FRSACE (250 mg kg−1) + Dox-treated rats showing congested blood vessels and inflammatory changes. (D) Section of the heart of Arjuna (100 mg kg−1) + Dox-treated rats showing inflammatory changes. (E) Section of the heart of FRSACE (500 mg kg−1) + Dox-treated rats showing normal cardiac muscle fibers and some congested blood vessels; NMF: normal cardiac muscle fibers, PNMI: perivascular mononuclear infiltrate, CBV: congested blood vessel.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.